Pesquisar
BioMarin Pharmaceutical Inc
BMRNAdicionar à lista de desejos
53.628USD
+0.748+1.41%
Horário de mercado （ET）Cotações atrasadas em 15 min
10.36BValor de mercado
38.44P/L TTM
Mais detalhes de BioMarin Pharmaceutical Inc Empresa
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Informações de BioMarin Pharmaceutical Inc
Código da empresaBMRN
Nome da EmpresaBioMarin Pharmaceutical Inc
Data de listagemJul 23, 1999
CEOHardy (Alexander)
Número de funcionários3040
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 23
Endereço770 Lindaro Street
CidadeSAN RAFAEL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94901
Telefone14155066700
Sitehttps://www.biomarin.com/
Código da empresaBMRN
Data de listagemJul 23, 1999
CEOHardy (Alexander)
Executivos da empresa BioMarin Pharmaceutical Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
35.22K
-5.48%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
21.36K
-9.03%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
6.91K
-27.88%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
6.90K
-27.97%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
6.03K
-641.58%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
2.81K
-1848.04%
Dr. James H. Sabry, M.D., Ph.D.
Dr. James H. Sabry, M.D., Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Timothy Walbert
Mr. Timothy Walbert
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
35.22K
-5.48%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
21.36K
-9.03%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
6.91K
-27.88%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
6.90K
-27.97%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Voxzogo
926.92M
29.26%
Vimizim
792.05M
25.00%
Naglazyme
485.40M
15.32%
Palynziq
433.31M
13.68%
Aldurazyme
208.51M
6.58%
Outro
321.57M
10.15%
Por RegiãoUSD
Nome
Receita
Proporção
United States
1.10B
34.88%
Europe
874.33M
27.60%
Rest of the world
544.47M
17.19%
Latin America
435.48M
13.75%
ALDURAZYME net product revenues marked by Sanofi
208.51M
6.58%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Voxzogo
926.92M
29.26%
Vimizim
792.05M
25.00%
Naglazyme
485.40M
15.32%
Palynziq
433.31M
13.68%
Aldurazyme
208.51M
6.58%
Outro
321.57M
10.15%
Distribuição de ações
Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
8.41%
Dodge & Cox
7.54%
PRIMECAP Management Company
7.34%
Vanguard Capital Management, LLC
4.47%
Vanguard Portfolio Management, LLC
4.29%
Outro
67.94%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
8.41%
Dodge & Cox
7.54%
PRIMECAP Management Company
7.34%
Vanguard Capital Management, LLC
4.47%
Vanguard Portfolio Management, LLC
4.29%
Outro
67.94%
Tipos de investidores
Investidores
Proporção
Investment Advisor
44.15%
Investment Advisor/Hedge Fund
35.63%
Hedge Fund
10.25%
Sovereign Wealth Fund
3.90%
Research Firm
2.33%
Pension Fund
2.25%
Venture Capital
0.71%
Bank and Trust
0.67%
Individual Investor
0.28%
Participação acionária institucional
Atualizado em: qui, 9 de abr
Atualizado em: qui, 9 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
1355
192.89M
99.80%
-14.51M
2025Q4
1296
187.90M
108.82%
+71.66K
2025Q3
1334
187.86M
111.13%
-2.15M
2025Q2
1344
190.17M
114.04%
-8.63M
2025Q1
1331
198.83M
113.78%
-19.35M
2024Q4
1317
196.49M
110.91%
+4.70M
2024Q3
1283
191.71M
111.61%
-4.43M
2024Q2
1271
195.66M
108.22%
+2.33M
2024Q1
1257
193.46M
109.63%
-14.58M
2023Q4
1275
195.75M
103.93%
+7.49M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
16.25M
8.45%
-994.19K
-5.76%
Dec 31, 2025
Dodge & Cox
14.57M
7.58%
-114.42K
-0.78%
Dec 31, 2025
PRIMECAP Management Company
14.55M
7.57%
-679.97K
-4.46%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
7.53M
3.92%
+5.49M
+268.47%
Dec 31, 2025
State Street Investment Management (US)
7.52M
3.91%
-1.24M
-14.16%
Dec 31, 2025
AQR Capital Management, LLC
6.69M
3.48%
+754.81K
+12.72%
Dec 31, 2025
Viking Global Investors LP
6.04M
3.14%
-2.29M
-27.46%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
3.32M
1.73%
+1.08M
+47.95%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
First Trust NYSE Arca Biotechnology Index Fund
3.44%
Global X Genomics & Biotechnology ETF
2.98%
Invesco Biotechnology & Genome ETF
2.47%
First Trust Health Care Alphadex Fund
2.15%
Goldman Sachs Future Health Care Equity ETF
2.15%
State Street SPDR S&P Biotech ETF
1.93%
WealthTrust DBS Long Term Growth ETF
1.86%
Alger Russell Innovation ETF
1.84%
Virtus LifeSci Biotech Products ETF
1.5%
VanEck Biotech ETF
1.4%
Ver Mais
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.44%
Global X Genomics & Biotechnology ETF
Proporção2.98%
Invesco Biotechnology & Genome ETF
Proporção2.47%
First Trust Health Care Alphadex Fund
Proporção2.15%
Goldman Sachs Future Health Care Equity ETF
Proporção2.15%
State Street SPDR S&P Biotech ETF
Proporção1.93%
WealthTrust DBS Long Term Growth ETF
Proporção1.86%
Alger Russell Innovation ETF
Proporção1.84%
Virtus LifeSci Biotech Products ETF
Proporção1.5%
VanEck Biotech ETF
Proporção1.4%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
